瑞马唑仑的临床应用与研究进展

朱智 琦1, 刘红 梅2
1.华北理工大学 河北唐山 063000 2.唐山市工人医院疼痛科 河北唐山 063000

摘要

目的：瑞马唑仑是一种新型超短效苯二氮䓬类镇静药物，瑞马唑仑结合了咪达唑仑和瑞芬太尼的特性，具有起效快、代谢快、不良反应小、无注射痛、个体变异率小、可控性强、蓄积有限、呼吸抑制风险小、具有特异性拮抗剂、代谢产物几乎不具备药理活性，对血流动力学影响小等药理学特点。瑞马唑仑已在多个国家获批用于程序性镇静及全身麻醉。目前关于瑞马唑仑的临床应用以及瑞马唑仑的药理特点的相关研究仍在进行中。本文以瑞马唑仑的药理特点、临床应用以及安全性等为核心作一综述。

关键词

瑞马唑仑；苯二氮䓬类；全身麻醉；程序性镇静

参考

[1]Sneyd.JR,.Rigby-Jones.AE..Remimazolam.for.anaesthesia.or.sedation..Curr.Opin.Anaesthesiol..2020.Aug;33(4):506-511.doi:10.1097/ACO.0000000000000877.PMID: 32530890.[2][22]Kim KM.Remimazolam: pharmacological characteristics and clinical applications in anesthesiology.Anesth Pain Med (Seoul).2022Jan;17(1):1-11.doi:10.17085/apm.21115. Epub 2022 Jan 20.PMID:35139608;PMCID:PMC8841266.[3][5]窦豆,栗亚茹,王璐等.新型镇静药物瑞马唑仑的研究进展[J].中国医药,2023,18(03):453-457.[4]李彦峰,王钝.瑞马唑仑[J].中国药物化学杂志,2021,31(07):572.DOI:10.14142/j.cnki.cn21-1313/r.2021.07.013.[6][7]Lee A,Shirley M.Remimazolam:A Review in Procedural Sedation.Drugs.2021 Jul;81(10):1193-1201.doi:10.1007/s40265-021-01544-8.Epub 2021 Jul 1.PMID:34196946.[8]Pantos MM,Kennedy DR,Nemec EC.Remimazolam:A Novel Option for Procedural Sedation in High Risk Patients.J Pharm Pract.2023 Feb;36(1):149-154. doi:10.1177/08971900211027303.Epub 2021 Jun 22.PMID:34155946.[9]Zhu X,Wang H,Yuan S,Li Y,Jia Y,Zhang Z,Yan F,Wang Z.Efficacy and Safety of Remimazolam in Endoscopic Sedation-A Systematic Review and Meta-Analysis.Front Med (Lausanne).2021 Jul 26;8:655042.doi:10.3389/fmed.2021.655042.PMID:34381792;PMCID:PMC8350069.[10]田有利,金明根.新药瑞马唑仑未来的潜力[J].中国处方药,2022,20(07):163-166.[11]Doi M,Morita K,Takeda J,Sakamoto A,Yamakage M,Suzuki T.Efficacy and safety of remimazolam versus propofol for general anesthesia:a multicenter,single-blind, randomized,parallel-group,phase IIb/III trial.J Anesth.2020 Aug;34(4):543-553.doi:10.1007/s00540-020-02788-6.Epub 2020 May 16.PMID:32417976.[12]Choi JY, Lee HS, Kim JY, Han DW, Yang JY, Kim MJ, Song Y. Comparison of remimazolam-based and propofol-based total intravenous anesthesia on postoperative quality of recovery: A randomized non-inferiority trial.J Clin Anesth. 2022 Nov;82:110955. doi: 10.1016/j.jclinane.2022.110955. Epub 2022 Aug 25. PMID: 36029704.[13]王泽鹏,史创国,段磊等.苯磺酸瑞马唑仑用于妇科腔镜手术的效果观察[J].中国现代医药杂志,2023,25(01):60-63.[14]Dai G,Pei L,Duan F,Liao M,Zhang Y,Zhu M,Zhao Z,Zhang X.Safety and efficacy of remimazolam compared with propofol in induction of general anesthesia.Minerva Anestesiol.2021 Oct;87(10):1073-1079.doi:10.23736/S0375-9393.21.15517-8.Epub 2021 Jul 14.PMID:34263581.[15]赵宇晗,王婷婷,胡静等.新型镇静药物瑞马唑仑的临床研究进展[J].中国新药杂志,2022,31(20):2006-2010.[16]叶冲冲,谢永鹏,骆继业等.不同剂量瑞马唑仑在ICU机械通气患者中的镇静效果及对血流动力学的影响[J].中国医药导报,2021,18(22):121-124.[17]侯成,卢光照,李文清等.氟马西尼的药理、药效和剂型应用进展[J].药学实践杂志,2017,35(06):485-489.[18]Stöhr T,Colin PJ,Ossig J，Pesic M,Borkett K,Winkle P,Struys MMRF,Schippers F.Pharmacokinetic properties of remimazolam in subjects with hepatic or renal impairment.Br J Anaesth.2021 Sep;127(3):415-423.doi:10.1016/j.bja.2021.05.027.Epub 2021 Jul 8.PMID:34246461.[19]Useinovic N,Jevtovic-Todorovic V.Novel anesthetics inpediatric practice:is it time?Curr Opin Anaesthesiol.2022 Aug 1;35(4):425-435.doi:10.1097/ACO.0000000000001156.Epub 2022 Jul 5.PMID:35787582; PMCID:PMC10104442.[20]旷光华,徐伟,夏瑞.瑞马唑仑的应用现状及其研究进展[J].实用医学杂志,2022,38(13):1695-1700.[21]Wesolowski AM,Zaccagnino MP,Malapero RJ,Kaye AD,Urman RD.Remimazolam:Pharmacologic.Considerations.and.Clinical.Role.in.Anesthesiology.Pharmacotherapy.2016 Sep;36(9):1021-7.doi:10.1002/phar.1806.Epub 2016 Sep 1.PMID:27496519.